Getting Breakthrough Biotechnologies To Market: Why Innovation Is Not Enough

By Domink Bell

In fast-moving areas like CRISPR, NGS, automation, and bioinformatics, innovation is rarely limited by a single technology. Progress depends on how well hardware, software, workflows, and scientific expertise come together to turn a promising idea into a practical solution. As tools mature and new breakthroughs emerge, organizations need development strategies that can adapt without slowing progress or increasing risk. A flexible, well-connected approach can help teams evaluate which advances are ready to support discovery, which require further validation, and how to move from concept to implementation with greater confidence.

Examine key considerations for navigating biotechnology’s rapid pace and building a clearer path from innovation to real-world impact.